Navigation Links
AlphaRx Unveils its China Strategy
Date:7/21/2009

    AlphaRx plans to open an R&D facility and manufacturing plant in China
    with local partners, to introduce innovative drug products to the fastest
    growing pharmaceutical market in the world.

MARKHAM, ON, July 21 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an emerging biopharmaceutical company, utilizing proprietary drug delivery technology to develop novel formulations of drugs, is forging ahead with its growth strategy for Greater China. As part of this strategy, AlphaRx is poised to open a "state of the art" R D and pilot plant facility in China with local partners. The R D facility will focus on the development of innovative drug products targeting infectious disease and various forms of cancer. Additionally, the Company, together with its local partners, plans to develop adjuvant vaccines to treat influenza, such as H5N1 and H1N1 strains.

AlphaRx currently has a topical NSAID awaiting near-term registration in China and is developing a second product - GAI-122 - an injectable nanoemulsion, in collaboration with Gaia BioPharma for the treatment of acute hepatitis, a therapy with a multi-million dollar potential indication in China.

The Chinese government has been a strong supporter of the life sciences industry. It plans to further increase its investment in the sector through a variety of grants and awards in some of its leading science and technology parks and through the National Program 863, originally established in March 1983 by Deng Xiaoping to award grants to science and technology projects that have significant commercial value. Most notably, in November 2008, China launched the Mega New Drug Development Program, a plan to invest $10 billion over the next 13 years, with the aim of creating a China-based innovative drug development industry.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx Reports Positive Preclinical Data on GAI-122 Against Liver Disease
2. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
3. AlphaRx Shareholder Update
4. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
5. AlphaRx Signs Cooperative Research and Development Agreement with US Army
6. AlphaRx Provides Corporate and Development Update
7. AlphaRxs Indaflex(TM) Continues its Clinical Development
8. AlphaRx CEO Accumulates More Company Shares
9. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
10. AlphaRx Announces Debt Conversion
11. AlphaRx To Present at 47th Annual ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Footwear Foundation, the national charitable foundation serving the footwear industry, has broken all ... representing more than 130 companies across 23 states during the months of April ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American ... productivity, stability, even security. Most importantly, employees are the single most important asset ... American workers so unhappy? , Just under half of American workers are emotionally ...
(Date:4/29/2016)... ... April 29, 2016 , ... A new ... with severe congenital diaphragmatic hernia have better survival rates if surgery is performed ... (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs into ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free Certification Program (GFCP), ... announce the launch of the GFCP Scoop in response to consumer ... of the GFCP Scoop site is to keep the gluten-free community ...
(Date:4/29/2016)... ... ... For those who skip meals occasionally (which is pretty much everyone), two ... new lifestyle diet tips offered by nutritionists Pam Bonney and Priya Lawrence of Tried ... Bonny and Lawrence noted that because proper nutrition, including water, provides energy during the ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... India , April 29, 2016 ... the life science laboratory due to the growing demands ... by advance technology, contemporary automated systems are already adept ... performed by slow, tedious and manual labor. Instrumentation continues ... were not even conceivable just a few years ago. ...
(Date:4/28/2016)... 2016 Dr. ... und Stephen Schmidt werden ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen für ... dass neue Führungskräfte zum Team Sicherheit und ... vielfältige Erfahrungen mitbringen.  Dies wird die Geschäftseinheit ...
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
Breaking Medicine Technology: